Mohamed Hussam Aswad1,2, Jarmila Kissova3,2, Petra Ovesna4, Lucie Rihova3,2, Miroslav Penka3,2. 1. Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic; aswad.mohamedhussam@fnbrno.cz. 2. Faculty of Medicine, Masaryk University, Brno, Czech Republic. 3. Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. 4. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Abstract
BACKGROUND/AIM: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). PATIENTS AND METHODS: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. RESULTS: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. CONCLUSION: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
BACKGROUND/AIM: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). PATIENTS AND METHODS: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. RESULTS: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. CONCLUSION: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
Authors: Alberto Alvarez-Larrán; Eduardo Arellano-Rodrigo; Juan Carlos Reverter; Abel Domingo; Neus Villamor; Dolors Colomer; Francisco Cervantes Journal: Ann Hematol Date: 2007-09-27 Impact factor: 3.673
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: Marijke C Trappenburg; Muriel van Schilfgaarde; Marina Marchetti; Henri M Spronk; Hugo ten Cate; Anja Leyte; Wim E Terpstra; Anna Falanga Journal: Haematologica Date: 2009-06-08 Impact factor: 9.941
Authors: Catherine M Hobbs; Harriet Manning; Cavan Bennett; Louella Vasquez; Sonia Severin; Lauren Brain; Alexandra Mazharian; Jose A Guerrero; Juan Li; Nicole Soranzo; Anthony R Green; Steve P Watson; Cedric Ghevaert Journal: Blood Date: 2013-10-01 Impact factor: 22.113